Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
13 Februar 2023 - 3:14PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of February 2023
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F
X
Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes
__
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
13 February 2023 14:00 GMT
Transaction by Person Discharging Managerial
Responsibilities
AstraZeneca PLC (the Company) announced that on 9 February
2023 certain awards of the Company's ordinary shares of
$0.25 each (Ordinary Shares) and the Company's American
Depositary Shares (ADSs) vested to Dr Aradhana Sarin, Executive
Director and Chief Financial Officer. Each ADS represents one half
of an Ordinary Share.
Following the reinvestment of dividends and the withholding to
satisfy certain tax obligations arising on vesting, Dr Sarin
acquired the ADSs and Ordinary Shares as detailed in the table
below.
|
PDMR
|
ADSs acquired under the Alexion equity awards
|
Ordinary Shares acquired under restricted share award
|
|
Aradhana Sarin
|
29,362
|
7,514
|
Further details on the awards is also set out below.
Alexion equity awards
In accordance with the Agreement and Plan of Merger between the
Company and Alexion Pharmaceuticals, Inc. (Alexion), Dr Sarin's
in-flight share awards granted by Alexion were converted to awards
over AstraZeneca ADSs under the AstraZeneca Global Restricted Stock
Plan at the time of closing of the Alexion acquisition. The awards
that vested on 9 February 2023 replaced in-flight Alexion awards
originally granted to Dr Sarin between February 2020 and February
2021 under the Alexion 2017 Incentive Plan.
Restricted share award
Dr Sarin's previous employment contract with Alexion included an
entitlement to cash severance arrangements, which would have been
triggered at the date of closing of the acquisition of
Alexion. To compensate Dr Sarin for the forfeiture of these
contractual entitlements an award of £2,015,540 was made in
August 2021, 50% in cash and 50% in restricted shares. The
restricted shares vested and were released to Dr Sarin on 9
February 2023, 18 months after her appointment.
For tax purposes, the fair market value of an ADS at vest of the
awards was US$64.36, being the closing price on the last trading
day preceding the vesting. The fair market value of an Ordinary
Share at vest was 10,572 pence, being the closing price on the last
trading day preceding the vesting.
Further details are set out in the attached notification, made in
accordance with the requirements of the EU Market Abuse Regulation
(as it forms part of UK law pursuant to the European Union
(Withdrawal) Act 2018.
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
|
a)
|
Name
|
Aradhana Sarin
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Financial Officer
|
|
b)
|
Initial notification/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
AstraZeneca PLC
|
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
|
4i
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type of
instrument
Identification code
|
AstraZeneca PLC American Depositary Shares
CUSIP: 046353108
|
|
b)
|
Nature of the transaction
|
Acquisition of AstraZeneca PLC American Depository Shares pursuant
to a vesting under the Global Restricted Stock Plan
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
0
|
29,362
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
|
e)
|
Date of the transaction
|
9 February 2023
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
|
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
|
a)
|
Name
|
Aradhana Sarin
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Financial Officer
|
|
b)
|
Initial notification/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
AstraZeneca PLC
|
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
|
4i
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial instrument, type of
instrument
Identification code
|
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
|
b)
|
Nature of the transaction
|
Acquisition of AstraZeneca PLC Ordinary Shares pursuant to a
vesting of a Restricted Share Award
|
|
c)
|
Price(s) and volume(s)
|
Price(s)
|
Volume(s)
|
|
0
|
7,514
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
|
e)
|
Date of the transaction
|
9 February 2023
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
13 February 2023
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024
